Riskpilot← Back to searchSign inGet full accessCeemax AB
ABActiveOrg 5593291403Hantverkargatan 2Retail sale of medical and orthopaedic goods · NACE 4774Est. 20211 employees
Revenue 2025
SEK 1,2M
+207% vs 2024
EBITDA margin
19.9%
+408% vs 2024
Equity ratio
40.7%
Financial strength
Net profit 2025
SEK 198K
+302% vs 2024
| Revenue | SEK 1,2M | +207% |
| EBITDA | SEK 246K | +408% |
| Net profit | SEK 198K | +302% |
| Total assets | SEK 560K | +51% |
| Equity | SEK 228K | +635% |
| Employees | 1 | — |
Legal name
Ceemax AB
Org number
5593291403
Legal form
Aktiebolag
NACE code
4774 · Retail sale of medical and orthopaedic goods
Founded
29 juli 2021
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva tjänster så som uthyrning av personal till optisk-verksamhet och utbildning. Bolaget ska även bedriva specialiserad butikshandel med glasögon och andra optiska artiklar och därmed förenlig verksamhet.
Address
Hantverkargatan 2
Email
aleksandra.muhonen@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 900 | 402 | 1 234 |
| Staff expenses | — | — | — | — |
| EBITDA | — | 46 | −80 | 246 |
| Depreciation & amort. | −0 | −0 | −20 | −20 |
| EBIT | 0 | 46 | −100 | 226 |
| Net financials | — | −3 | 2 | −2 |
| Profit before tax | 0 | 43 | −98 | 224 |
| Tax | −0 | −9 | −0 | −26 |
| Net profit | 0 | 34 | −98 | 198 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25 | 352 | 370 | 560 |
| Equity | 25 | 59 | 31 | 228 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 293 | 339 | 332 |
| Total debt | — | 293 | 339 | 332 |
EBITDA margin
19.9%
This company
15.8%
Market median
+26% vs market
20222025
Equity ratio
40.7%
This company
38.2%
Market median
+7% vs market
20222025
Return on equity
86.8%
This company
18.4%
Market median
+372% vs market
20222025
Net profit margin
16.0%
This company
8.1%
Market median
+98% vs market
20222025
Asset turnover
2.20×
This company
1.12×
Market median
+96% vs market
20222025
Debt / equity
1.46×
This company
0.62×
Market median
-135% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CM | Audit | 2022 | — | — |
KG | Audit | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ceemax AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Michael Dalestig | Audit | 0 companies |
| Kent Gunnar Lundqvist | Audit | 0 companies |
| Anna Katarina Katrin Persson | Deputy Board Member | 0 companies |
| Hans Christian Fredrik Andersson | Deputy Board Member | 0 companies |
| Aleksandra Muhonen | Board of Directors | 0 companies |
| Jonny Mattias Muhonen | Board of Directors | 0 companies |